Lemonex is a leading bioventure company at the forefront of developing advanced pharmaceuticals through innovative next-generation drug delivery systems. Their mission is to safely and effectively deliver drugs to targeted sites within the body. Lemonex possesses the core technology of their drug delivery system called DegradaBALL®, which offers a safer and more efficient platform technology for the production of various drugs tailored to different drug characteristics compared to conventional drug delivery systems.

Lemonex is expanding their drug delivery platform technology to include siRNA, mRNA, Dual-RNA, and cytokine drugs to develop a pipeline of new drugs. Through clinical research, they have validated the safety and efficacy of DegradaBALL® and will continue to expand their drug delivery platform technology with diverse new drugs, improved drugs, and vaccines. DegradaBALL® is a globally recognized best-in-class drug delivery platform, and Lemonex has established the infrastructure to produce 450,000 vials annually.

They are currently developing a pipeline of new drugs and improved drugs by applying the DegradaBALL® platform to various types of pharmacologically active substances, such as siRNA LEM-S401 for hypertrophic scar and keloid treatment, mRNA LEM-mR203 for Covid-19 mRNA vaccines, Dual-RNA LEM-S403 for immunotherapeutic IL-2, and BALLkine-2 for immunotherapeutic agents. Lemonex Inc